Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing

This pilot randomized controlled trial (N=51) includes stroke patients admitted to a sub-acute rehabilitation facility. Subjects will be clinically screened for dysphagia, and randomized into three groups, NMES, sham NMES or usual care -behavioral swallowing therapy arm. Following randomization, all subjects will undergo a video-x-ray (modified barium swallow) of swallowing to confirm the presence of oropharyngeal dysphagia and provide objective data about the nature and degree of dysphagia. All patients will be treated for one hour per day for 3 weeks, and their progress and outcome will be recorded. Participants will be independently evaluated by a blinded assessor at baseline, post treatment and at 3 months following treatment. The primary outcome will be improvement in clinical swallowing ability, oral intake level, and body weight. The results will add to the preliminary data on the effectiveness of this form of swallowing treatment for patients following stroke.

Inclusion criteria

• Stroke identified by neurological and radiological examination
• Oropharyngeal dysphagia as confirmed by clinical and radiological examination
• No prior history of oropharyngeal dysphagia by patient and/or caregiver report
• No previous head/neck surgery or trauma that may impact swallowing ability
• No other/concomitant neurological disorders (e.g. Parkinson's disease) that would impact oropharyngeal swallowing ability. This does not include post-stroke deficits.
• Physician and patient/family agreement to participate.

Exclusion criteria

• Exposed to previous behavioral or NMES swallowing therapy within 6 months of admission
• Presence of progressive neurological disorder, such as ALS; Parkinson's or other neurologic disorders within the last 6 months;
• History of neurosurgery (either ablative or stimulatory), encephalitis or significant head trauma.
• History of a significant medical condition such as heart, liver, or renal disease; history or evidence of malignancy within the past 5 years other than excised basal cell carcinoma.
• Because of FDA Warnings, patients with cardiac demand pace makers will be excluded.
• Patients with evidence of significant cognitive impairment or dementia as reflected in a Mini-Mental test less than 23 and/or a score of 50% or less on the comprehension quotient on the Western Aphasia Battery.